Glucagon: difference between revisions
Diff·revision 7 → 8·20:17, 14 Oct 2024
Difference between revision 7 and revision 8 of Glucagon. 3 lines changed; the page grew by 428 bytes.
| Revision 7 — 19:41, 25 Sep 2024 CuriousCallum (talk) attribute the potency comparison to the head-to-head trial rather than to two separate ones 3,686 bytes +34 | Revision 8 — 20:17, 14 Oct 2024 SurvodutideSaff (talk) split overlong sentence 4,114 bytes +428 | ||
|---|---|---|---|
| 25 | In type 1 diabetes the alpha-cell response to hypoglycaemia is lost early, which removes the first line of defence against insulin-induced hypoglycaemia and is a principal reason that condition is harder to manage than the pathophysiology alone would suggest. | 25 | In type 1 diabetes the alpha-cell response to hypoglycaemia is lost early, which removes the first line of defence against insulin-induced hypoglycaemia and is a principal reason that condition is harder to manage than the pathophysiology alone would suggest. |
| 26 | 26 | ||
| + | 27 | == Receptor and signalling == | |
| + | 28 | The glucagon receptor is a class B GPCR with the same two-domain architecture as the [[GLP-1 receptor]] and roughly 45% sequence identity to it in the transmembrane region. It couples principally to G<sub>s</sub>; hepatic cAMP activates protein kinase A, which phosphorylates glycogen phosphorylase kinase and the transcriptional machinery driving gluconeogenic gene expression.{{r|sandoval2015}} | |
| + | 29 | ||
| 27 | == References == | 30 | == References == |
| 28 | {{reflist}} | 31 | {{reflist}} |